Discovery, Development, and Clinical Application of Sugammadex Sodium, a Selective Relaxant Binding Agent

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2009 Nov 19

PMID 19920893

Citations 24

Authors

Mark Welliver

John McDonough

Nicholas Kalynych

Robert Redfern

Affiliations

Soon will be listed here.

Abstract

Neuromuscular blockade, induced by neuromuscular blocking agents, has allowed prescribed immobility, improved surgical exposure, optimal airway management conditions, and facilitated mechanical ventilation. However, termination of the effects of neuromuscular blocking agents has, until now, remained limited. A novel cyclodextrin encapsulation process offers improved termination of the paralytic effects of aminosteroidal non-depolarizing neuromuscular blocking agents. Sugammadex sodium is the first in a new class of drug called selective relaxant binding agents. Currently, in clinical trials, sugammadex, a modified gamma cyclodextrin, has shown consistent and rapid termination of neuromuscular blockade with few side effects. The pharmacology of cyclodextrins in general and sugammadex in particular, together with the results of current clinical research are reviewed. The ability of sugammadex to terminate the action of neuromuscular blocking agents by direct encapsulation is compared to the indirect competitive antagonism of their effects by cholinesterase inhibitors. Also discussed are the clinical implications that extend beyond fast, effective reversal, including numerous potential perioperative benefits.

Citing Articles

Extended Sulfo-Pillar[6]arenes ─ a New Host Family and Its Application in the Binding of Direct Oral Anticoagulants.

Wilson C, Puckett A, Murray I, Oliver A, Hof F J Am Chem Soc. 2024; .

PMID: 39356656 PMC: 11487555. DOI: 10.1021/jacs.4c03905.

Cyclodextrins: Establishing building blocks for AI-driven drug design by determining affinity constants .

Anderson A, Pineiro A, Garcia-Fandino R, OConnor M Comput Struct Biotechnol J. 2024; 23:1117-1128.

PMID: 38510974 PMC: 10950811. DOI: 10.1016/j.csbj.2024.02.011.

Effect of sugammadex, rocuronium and sevoflurane on oxidative stress and apoptosis in cerebral ischemia reperfusion model in rats.

Ciftci H, Tas N, Cebeci Z, Kokturk S, Cirrik S, Noyan T North Clin Istanb. 2024; 11(1):1-9.

PMID: 38357323 PMC: 10861428. DOI: 10.14744/nci.2023.07888.

Cardiac arrest following sugammadex administration.

Pereira A, Oliveira R, Esteves C, Coutinho M Anaesth Rep. 2023; 11(1):e12233.

PMID: 37273748 PMC: 10234280. DOI: 10.1002/anr3.12233.

Comparison of neostigmine and sugammadex for hemodynamic parameters in neurointerventional anesthesia.

Tsai Y, Chen C, Wong H, Chou A Front Neurol. 2023; 14:1045847.

PMID: 37139057 PMC: 10150384. DOI: 10.3389/fneur.2023.1045847.

References

Epemolu O, Bom A, Hope F, Mason R . Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003; 99(3):632-7; discussion 6A. DOI: 10.1097/00000542-200309000-00018. View

Murphy G, Szokol J, Marymont J, Franklin M, Avram M, Vender J . Residual paralysis at the time of tracheal extubation. Anesth Analg. 2005; 100(6):1840-1845. DOI: 10.1213/01.ANE.0000151159.55655.CB. View

Hayes A, Mirakhur R, Breslin D, Reid J, McCourt K . Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia. 2001; 56(4):312-8. DOI: 10.1046/j.1365-2044.2001.01921.x. View

MacPherson R . Pharmaceutics for the anaesthetist. Anaesthesia. 2001; 56(10):965-79. DOI: 10.1046/j.1365-2044.2001.02216.x. View

Eikermann M, Blobner M, Groeben H, Rex C, Grote T, Neuhauser M . Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesth Analg. 2006; 102(3):937-42. DOI: 10.1213/01.ane.0000195233.80166.14. View

Adam J, Bennett D, Bom A, Clark J, Feilden H, Hutchinson E . Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002; 45(9):1806-16. DOI: 10.1021/jm011107f. View

Murphy G . Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006; 72(3):97-109. View

Tramer M, Fuchs-Buder T . Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth. 1999; 82(3):379-86. DOI: 10.1093/bja/82.3.379. View

Welliver M . Update for nurse anesthetists--part 3--cyclodextrin introduction to anesthesia practice: form, function, and application. AANA J. 2007; 75(4):289-96. View

10.

Berg H, Roed J, Viby-Mogensen J, Mortensen C, Engbaek J, Skovgaard L . Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997; 41(9):1095-1103. DOI: 10.1111/j.1399-6576.1997.tb04851.x. View

11.

Challa R, Ahuja A, Ali J, Khar R . Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 2005; 6(2):E329-57. PMC: 2750546. DOI: 10.1208/pt060243. View

12.

Puhringer F, Rex C, Sielenkamper A, Claudius C, Larsen P, Prins M . Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008; 109(2):188-97. DOI: 10.1097/ALN.0b013e31817f5bc7. View

13.

Suy K, Morias K, Cammu G, Hans P, van Duijnhoven W, Heeringa M . Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007; 106(2):283-8. DOI: 10.1097/00000542-200702000-00016. View

14.

Kirkegaard H, Heier T, Caldwell J . Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology. 2001; 96(1):45-50. DOI: 10.1097/00000542-200201000-00013. View

15.

Eleveld D, Kuizenga K, Proost J, Wierda J . A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg. 2007; 104(3):582-4. DOI: 10.1213/01.ane.0000250617.79166.7f. View

16.

Eriksson L . The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Anesth Analg. 1999; 89(1):243-51. DOI: 10.1097/00000539-199907000-00045. View

17.

Appelboam R, Mulder R, Saddler J . Atracurium associated with postoperative residual curarization. Br J Anaesth. 2003; 90(4):523; author reply 523-4. View

18.

Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama C, Cupa M . Residual curarization in the recovery room after vecuronium. Br J Anaesth. 2000; 84(3):394-5. DOI: 10.1093/oxfordjournals.bja.a013445. View

19.

Debaene B, Plaud B, Dilly M, Donati F . Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003; 98(5):1042-8. DOI: 10.1097/00000542-200305000-00004. View

20.

Vanacker B, Vermeyen K, Struys M, Rietbergen H, Vandermeersch E, Saldien V . Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg. 2007; 104(3):563-8. DOI: 10.1213/01.ane.0000231829.29177.8e. View